FROM:
 PR Newswire
 February 7, 2003, Friday

HEADLINE: The Michael J. Fox Foundation for Parkinson's Research Commits
$2
 Million to Study PD Dyskinesia

DATELINE: NEW YORK, Feb. 7

"   The Michael J. Fox Foundation for Parkinson's Research today
announced that
 it has committed $2 million to a new research initiative to study
dyskinesias,
 the involuntary, uncontrollable movements that are a frequent
side-effect of
 treatment and are distinct from the tremors commonly associated with
Parkinson's
 disease.

    The presence of dyskinesias is a major limiting factor in achieving
adequate
 long-term control of Parkinson's disease symptoms.  At present, the most
 commonly administered drug to treat Parkinson's symptoms is levodopa
(also
 called L-dopa), which helps restore levels of dopamine, a chemical
messenger in
 the brain responsible for smooth, coordinated movement and other motor
 functions.  Yet after 5 to 10 years of treatment with levodopa,
approximately 80
 percent of patients will develop uncontrollable movements, or
dyskinesias, a
 major source of disability in the their lives.  In addition, in cell
replacement
 therapy, the development of these same movements, even in the absence of
 levodopa therapy (so-called runaway dyskinesias) is now regarded as a
critical
 roadblock to that therapy's ultimate success.

    "While important progress in understanding levodopa-induced
dyskinesias has
 been made, the origin and precise mechanisms of levodopa-induced
dyskinesias are
 still a medical mystery," said Dr. William Langston, chief scientific
advisor to
 MJFF and CEO of The Parkinson's Institute.  "This research initiative
seeks to
 build on the knowledge and expertise of neuroscientists and clinicians
to
 further our understanding of dyskinesias. There are few breakthroughs
that would
 be more of an immediate impact on the day-to-day lives of patients with
 Parkinson's disease than finding ways to prevent this often devastating
 side-effect of therapy."
     "This program is part of our strategy to zero in on areas of
potentially
 high-impact research," said Deborah W. Brooks, executive director.
"Coupled
 with our just-launched program studying inflammation in Parkinson's
disease, the
 dyskinesias initiative reflects our commitment to research than can
quickly
 translate into benefits for the approximately one million Americans
living with
 Parkinson's disease."

    The RFA seeks a broad-based approach to dyskinesias that includes:
 understanding the mechanisms that underlie dyskinesias at the molecular
level;
 testing the impact of interventions on the neuroanatomical and
 neurophysiological substrates of dyskinesias; exploring the mechanisms
of
 various subtypes of dyskinesias; developing animal models, and seeking
novel
 therapies, both preventive and ameliorative.  Researchers should submit
letters
 of intent by March 14, 2003, with applications due April 14, 2003. Both
should
 be submitted by email only to [log in to unmask]  A complete
application
 coversheet and PDF file may be downloaded from the MJFF Web site,
 www.michaeljfox.org.  Funding of grant awards is anticipated in the fall
of
 2003.  In addition to funding from The Michael J. Fox Foundation for
Parkinson's
 Research, The Bachmann-Strauss Dystonia & Parkinson Foundation Inc.
provided a $
 100,000 grant for this research initiative.

    The Dyskinesias program is one element of the Foundation's research
agenda
 to eliminate Parkinson's disease within the decade.  At the end of 2002,
The
 Michael J. Fox Foundation for Parkinson's Research had funded more than
$17
 million in research aimed at finding a cure for the disease.  In
addition, the
 Foundation partnered with the National Institutes of Health (NIH) on
their
 funding of an incremental $9.5 million in "Fast Track" research
projects. In
 all, The Michael J. Fox Foundation has stimulated nearly $27 million in
new
 funding for Parkinson's disease research.

    Founded in 2000, The Michael J. Fox Foundation for Parkinson's
Research has
 established a strategic campaign to accelerate, expand, and focus
funding of the
 world's best research targeting effective treatment and prevention of
 Parkinson's disease.  MJFF is dedicated to pursuing every possible
avenue to
 increase federal funding as well as to support aggressive fundraising
efforts in
 both private and corporate arenas to ensure its goal is met.  For more
 information on The Michael J. Fox Foundation for Parkinson's Research,
visit
 http://www.michaeljfox.org .

    For more information on The Bachmann-Strauss Dystonia & Parkinson
Foundation
 please visit http://www.dystonia-parkinsons.org .

   SOURCE The Michael J. Fox Foundation for Parkinson's Research

CONTACT: Media - Joyce Oberdorf, +1-212-509-0995, ext. 214,
 [log in to unmask], or Beth Lambdin, +1-212-509-0995, ext. 230,
 [log in to unmask], or Research Contact - Michael Claeys,
+1-212-509-0995
 ext. 228, [log in to unmask], all of The Michael J. Fox Foundation
for
 Parkinson's Research

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn